Logo image of CDT

CDT EQUITY INC (CDT) Stock Fundamental Analysis

USA - NASDAQ:CDT - US20678X3044 - Common Stock

3.01 USD
-0.09 (-2.9%)
Last: 10/24/2025, 7:40:03 PM
3.02 USD
+0.01 (+0.33%)
After Hours: 10/24/2025, 7:40:03 PM
Fundamental Rating

1

Overall CDT gets a fundamental rating of 1 out of 10. We evaluated CDT against 57 industry peers in the Life Sciences Tools & Services industry. CDT has a bad profitability rating. Also its financial health evaluation is rather negative. CDT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CDT had negative earnings in the past year.
In the past year CDT has reported a negative cash flow from operations.
CDT Yearly Net Income VS EBIT VS OCF VS FCFCDT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

CDT's Return On Assets of -250.86% is on the low side compared to the rest of the industry. CDT is outperformed by 94.74% of its industry peers.
Looking at the Return On Equity, with a value of -567.89%, CDT is doing worse than 89.47% of the companies in the same industry.
Industry RankSector Rank
ROA -250.86%
ROE -567.89%
ROIC N/A
ROA(3y)-32724%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDT Yearly ROA, ROE, ROICCDT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20K -40K -60K -80K

1.3 Margins

CDT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDT Yearly Profit, Operating, Gross MarginsCDT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for CDT has been reduced compared to 1 year ago.
The debt/assets ratio for CDT is higher compared to a year ago.
CDT Yearly Shares OutstandingCDT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CDT Yearly Total Debt VS Total AssetsCDT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -12.97, we must say that CDT is in the distress zone and has some risk of bankruptcy.
CDT has a worse Altman-Z score (-12.97) than 91.23% of its industry peers.
CDT has a Debt/Equity ratio of 0.53. This is a neutral value indicating CDT is somewhat dependend on debt financing.
CDT has a Debt to Equity ratio of 0.53. This is in the lower half of the industry: CDT underperforms 63.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Altman-Z -12.97
ROIC/WACCN/A
WACCN/A
CDT Yearly LT Debt VS Equity VS FCFCDT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

2.3 Liquidity

A Current Ratio of 1.45 indicates that CDT should not have too much problems paying its short term obligations.
CDT has a worse Current ratio (1.45) than 75.44% of its industry peers.
A Quick Ratio of 1.45 indicates that CDT should not have too much problems paying its short term obligations.
CDT's Quick ratio of 1.45 is in line compared to the rest of the industry. CDT outperforms 42.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 1.45
CDT Yearly Current Assets VS Current LiabilitesCDT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

CDT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16775.82%.
EPS 1Y (TTM)-16775.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-401.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDT Price Earnings VS Forward Price EarningsCDT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDT Per share dataCDT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CDT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CDT EQUITY INC

NASDAQ:CDT (10/24/2025, 7:40:03 PM)

After market: 3.02 +0.01 (+0.33%)

3.01

-0.09 (-2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-14 2025-08-14
Earnings (Next)11-10 2025-11-10
Inst Owners0.67%
Inst Owner Change262.9%
Ins Owners4.17%
Ins Owner Change13.45%
Market Cap4.06M
Revenue(TTM)N/A
Net Income(TTM)-20041000
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.61
P/tB 2.61
EV/EBITDA N/A
EPS(TTM)-168.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.17
FCFYN/A
OCF(TTM)-4.03
OCFYN/A
SpS0
BVpS1.15
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -250.86%
ROE -567.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32724%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.45
Quick Ratio 1.45
Altman-Z -12.97
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16775.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-401.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-126.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-242.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-230.32%
OCF growth 3YN/A
OCF growth 5YN/A

CDT EQUITY INC / CDT FAQ

What is the fundamental rating for CDT stock?

ChartMill assigns a fundamental rating of 1 / 10 to CDT.


What is the valuation status of CDT EQUITY INC (CDT) stock?

ChartMill assigns a valuation rating of 0 / 10 to CDT EQUITY INC (CDT). This can be considered as Overvalued.


How profitable is CDT EQUITY INC (CDT) stock?

CDT EQUITY INC (CDT) has a profitability rating of 0 / 10.